Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women

Overview

The overall objective of this study is to evaluate whether the addition of secondary distribution HIV self-test kits to existing partner notification guidelines increases the proportion of male partners who access facility-based HIV testing services, when compared to the partner notification strategy alone

Full Title of Study: “Z 31901 – Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women: A Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 3, 2020

Detailed Description

Pregnant women 18 years of age or older who enter antenatal care at Chipata Level 1 Hospital in Lusaka, Zambia will participate. HIV-positive and HIV-negative pregnant women will be randomized to one of two groups: partner notification alone or partner notification plus secondary distribution of HIV self-test kits. Women will return to the clinic 30 days after enrollment for an exit visit during which time information about their experience with the partner notification strategies will be collected. A random sample of women and health care workers will also participate in qualitative interviews.

Interventions

  • Behavioral: HIV self-testing with partner notification.
    • HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.

Arms, Groups and Cohorts

  • Experimental: Intervention
    • In addition to standard partner notification services, the intervention arm will receive HIV self-test kits and structured counseling about HIVST, regardless of HIV status.
  • No Intervention: Control
    • Standard partner notification services, regardless of HIV status.

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants Who Reported Primary Male Partner Completed HIV Testing at a Healthcare Facility
    • Time Frame: Enrollment – 30 days post enrollment of study participant
    • The number of participants who report their primary male partners getting tested for HIV at a healthcare facility when presented with partner notification plus secondary distribution of HIV self-test kits compared to partner notification alone

Secondary Measures

  • Number of Participants Who Reported HIV Testing With Primary Male Partner at a Healthcare Facility
    • Time Frame: Enrollment – 30 days post enrollment of study participant
    • The number of couples getting tested for HIV when presented with partner notification plus secondary distribution of HIV self-test kits will be compared to partner notification alone.
  • Number of Participants Reporting Social Harms
    • Time Frame: Enrollment – 30 days post enrollment of study participant
    • The number of participants reporting social harms associated with the HIV testing approaches. Participants were asked about social harms related to trial participation, including perceived stigma, discrimination, and intimate partner violence.
  • Number of Healthcare Providers Describing Feasibility of Intervention Via In-depth Interviews (Qualitative)
    • Time Frame: 6 months after the start of enrollment
    • To gain deeper insights about the feasibility of male partner HIV testing strategies, healthcare workers from the study site were asked to participate in in-depth interviews. Participating healthcare workers were involved in different aspects of male partner HIV testing and included study staff members. Feasibility was defined as a positive rating about the intervention’s potential performance in real-life conditions at the clinic and community levels.
  • Number of Participants Describing Acceptability of Intervention Via In-depth Interviews (Qualitative)
    • Time Frame: In the first two months of enrollment
    • To gain deeper insights about the acceptability of the different male partner HIV testing strategies, subsamples of participants were selected based on study arm (intervention vs. control) and woman’s HIV status (positive vs. negative). For the outcome measure, acceptability was defined as a positive rating of male partner HIV testing strategies from participants based on their experiences.

Participating in This Clinical Trial

Inclusion Criteria

  • 18 years of age or older – Pregnant at time of enrollment based on antenatal record – Documented HIV status (either positive or negative) in antenatal record – Reports at least one current sexual partner – Willingness to provide her own contact information – Ability and willingness to provide informed consent – Intent to remain in current geographical area of residence for the duration of follow-up activities – Willingness to adhere to study procedures Exclusion Criteria – Women who express concerns about IPV or social harms as a result of participation during the screening process will not be included. – Women who have previously enrolled in the study will not be permitted to enroll again.

Gender Eligibility: Female

Pregnant women

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of North Carolina, Chapel Hill
  • Collaborator
    • National Institute of Allergy and Infectious Diseases (NIAID)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ben Chi, MD, Principal Investigator, University of North Carolina, Chapel Hill

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.